At Bao Pharma, we leverage our deep understanding of the unique tissue structure of the subcutaneous space to overcome the limitations of drug delivery within the dermis. This allows us to expand the application of advanced delivery technologies for enhanced therapeutic impact.

As an innovative delivery approach, subcutaneous administration can be combined with a range of therapeutic drugs, including small molecules and biologics, providing patients with a more convenient, comfortable, and safer treatment experience.

At Bao Pharma, we focus on developing clinical treatment solutions for pathogenic IgG-mediated immune system diseases that currently lack effective therapies. We are committed to addressing the clinical needs of patients in various fields, including autoimmune diseases (ADs), rare diseases, and organ transplantation.

We are continuously expanding the applications of recombinant human IgG-degrading enzymes and seeking breakthrough therapies for difficult-to-treat autoimmune diseases.

At Bao Pharma, we utilize genetic engineering techniques to replace traditional animal organ extraction methods, achieving an upgrade in chymotrypsin products with improved safety, quality, and supply.

Chymotrypsin is an enzyme that rapidly breaks down proteins, liquefying pus and necrotic tissue. It is widely used in numerous medical departments, including respiratory medicine, surgery, otolaryngology, obstetrics and gynecology, pediatrics, dentistry, ophthalmology, dermatology, gastroenterology, and colorectal surgery.

KJ015 is an innovative anti-HER2 bispecific antibody featuring a common light chain structure similar to natural IgG and demonstrating balanced high affinity for two distinct HER2 epitopes. This unique design enhances therapeutic precision, with KJ015 showing superior efficacy in preclinical studies compared to the combination of trastuzumab and pertuzumab. Furthermore, KJ015 exhibited significant synergistic effects with anti-PD-1 therapy in in vivo experiments, indicating strong therapeutic potential. The KJ015 formulation includes Hysorptase, allowing for subcutaneous administration and possessing stable physicochemical properties, marking a breakthrough in the treatment of HER2-positive cancers.